Results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s (AZN) fixed-dose triple-combination therapy Breztri Aerosphere met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist medicines. KALOS and LOGOS were replicate, randomized, double-blind trials designed to investigate Breztri as a potential treatment for asthma. The trials evaluated the efficacy and safety of Breztri versus maintenance treatment with ICS/LABA in adults and adolescents with uncontrolled asthma. There were no new safety or tolerability signals identified for BREZTRI in KALOS or LOGOS. Full results from the two Phase III trials will be shared with regulatory authorities and presented at an upcoming medical meeting.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca announces Phase III KALOS, LOGOS trials met primary endpoints
- AstraZeneca price target lowered to 13,700 GBp at Morgan Stanley
- AstraZeneca considering moving more production to U.S., Pharmaphorum reports
- AstraZeneca: Strong Buy Rating Backed by Oncology Growth and Promising Pipeline
- AstraZeneca’s Strong EPS Performance and Strategic Developments Justify Buy Rating